The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiother...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Jingjing, Mei, Quanhui, Liu, Li, Cheng, Tianli, Wang, Peng, Chen, Lijun, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy for Lung Cancer: Special Collection Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890731/
https://www.ncbi.nlm.nih.gov/pubmed/33643442
http://dx.doi.org/10.1177/1758835921992968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890731/
https://www.ncbi.nlm.nih.gov/pubmed/33643442
http://dx.doi.org/10.1177/1758835921992968

Ejemplares similares